BHC [NYSE]
Bausch Health Companies Inc.
Index- P/E49.15 EPS (ttm)0.12 Insider Own2.30% Shs Outstand362.20M Perf Week-7.26%
Market Cap2.15B Forward P/E1.38 EPS next Y4.17 Insider Trans-0.34% Shs Float345.70M Perf Month-37.36%
Income43.00M PEG5.65 EPS next Q0.99 Inst Own66.80% Short Float4.72% Perf Quarter-42.21%
Sales8.19B P/S0.26 EPS this Y-67.40% Inst Trans18.58% Short Ratio2.16 Perf Half Y-77.42%
Book/sh-1.91 P/B- EPS next Y20.03% ROA0.10% Target Price- Perf Year-79.60%
Cash/sh1.77 P/C3.26 EPS next 5Y8.70% ROE-14.10% 52W Range4.00 - 29.59 Perf YTD-79.17%
Dividend- P/FCF5.25 EPS past 5Y17.60% ROI2.10% 52W High-80.57% Beta1.35
Dividend %- Quick Ratio0.90 Sales past 5Y-2.70% Gross Margin71.50% 52W Low43.75% ATR0.61
Employees19600 Current Ratio1.10 Sales Q/Q-6.30% Oper. Margin18.20% RSI (14)40.67 Volatility6.36% 13.99%
OptionableYes Debt/Eq- EPS Q/Q75.80% Profit Margin0.50% Rel Volume0.53 Prev Close5.94
ShortableYes LT Debt/Eq- EarningsAug 09 BMO Payout0.00% Avg Volume7.56M Price5.75
Recom2.20 SMA20-8.98% SMA50-23.80% SMA200-69.28% Volume4,013,338 Change-3.20%
Jul-29-22Downgrade Truist Buy → Hold
Jul-29-22Downgrade RBC Capital Mkts Outperform → Sector Perform $12 → $5
Jul-28-22Downgrade JP Morgan Overweight → Neutral
Jun-13-22Resumed JP Morgan Overweight $12
Mar-24-21Downgrade BofA Securities Neutral → Underperform $27
Feb-17-21Upgrade RBC Capital Mkts Sector Perform → Outperform $26 → $42
Jan-22-21Downgrade Piper Sandler Overweight → Neutral $25 → $30
Sep-17-20Upgrade BofA Securities Underperform → Neutral $19
Aug-24-20Reiterated H.C. Wainwright Buy $64 → $50
Aug-24-20Reiterated H.C. Wainwright Buy $50 → $64
Jun-17-20Reiterated H.C. Wainwright Buy $50 → $64
Apr-24-20Initiated Citigroup Buy $30
Apr-02-20Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-29-20Downgrade Wolfe Research Outperform → Peer Perform
Jan-22-20Upgrade Wells Fargo Underweight → Equal Weight $32
Dec-12-19Upgrade JP Morgan Neutral → Overweight $32 → $38
Dec-02-19Initiated Goldman Neutral
Oct-25-19Initiated Cowen Outperform $35
Sep-12-19Initiated Guggenheim Buy
Aug-15-19Upgrade TD Securities Hold → Buy
Aug-15-22 10:05AM  
Aug-12-22 06:10AM  
Aug-10-22 06:00PM  
06:00PM  
11:56AM  
07:00AM  
07:00AM  
Aug-09-22 04:42PM  
09:19AM  
08:35AM  
08:22AM  
07:25AM  
07:00AM  
07:00AM  
Aug-08-22 09:14AM  
Aug-04-22 05:25PM  
03:00PM  
07:36AM  
Aug-03-22 05:35PM  
Aug-02-22 12:14PM  
10:00AM  
Aug-01-22 06:15PM  
11:06AM  
Jul-29-22 01:57PM  
01:44PM  
10:34AM  
09:35AM  
Jul-28-22 04:50PM  
03:56PM  
03:47PM  
03:45PM  
02:34PM  
10:51AM  
10:33AM  
10:30AM  
10:18AM  
10:12AM  
10:12AM  
10:03AM  
09:29AM  
09:04AM  
Jul-27-22 07:00PM  
Jul-26-22 03:45PM  
Jul-20-22 07:00AM  
07:00AM  
Jul-13-22 07:00AM  
Jul-11-22 09:17AM  
Jul-06-22 09:14AM  
Jul-02-22 10:30AM  
Jul-01-22 09:20AM  
Jun-24-22 09:22PM  
01:37PM  
09:47AM  
09:21AM  
06:23AM  
Jun-23-22 04:54PM  
Jun-21-22 07:00AM  
07:00AM  
Jun-20-22 07:00AM  
03:00AM  
Jun-19-22 04:52PM  
Jun-17-22 09:36AM  
08:22AM  
05:09AM  
Jun-16-22 07:59PM  
05:48PM  
05:30PM  
Jun-15-22 09:42AM  
Jun-10-22 04:13PM  
Jun-09-22 11:30AM  
Jun-08-22 07:17AM  
Jun-06-22 08:48AM  
Jun-02-22 05:00PM  
08:57AM  
Jun-01-22 05:21PM  
May-19-22 06:59AM  
May-18-22 07:00AM  
May-12-22 08:21PM  
May-11-22 07:00AM  
May-10-22 04:05PM  
03:39PM  
02:01PM  
12:46PM  
12:11PM  
11:37AM  
08:13AM  
06:59AM  
May-09-22 03:32PM  
May-07-22 12:00AM  
May-06-22 04:56PM  
04:29PM  
01:28PM  
01:05PM  
12:52PM  
12:09PM  
12:08PM  
12:07PM  
07:03AM  
06:38AM  
May-05-22 09:25PM  
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bausch Health Companies Inc.10% OwnerJun 01Sale17.054,550,35777,606,339310,449,643Jun 02 04:05 PM
Bausch Health Companies Inc.10% OwnerMay 10Sale17.0535,000,000596,925,000315,000,000May 12 04:18 PM
Spurr RobertU.S. President-Pharma BusinessApr 14Sale22.191,59535,39390,506Apr 15 04:32 PM
Spurr RobertU.S. President-Pharma BusinessMar 15Sale22.204,846107,58192,101Mar 16 04:39 PM
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'lMar 08Sale21.763,88984,62593,139Mar 10 04:03 PM
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'lMar 02Sale23.3711,077258,869101,102Mar 04 04:58 PM
Spurr RobertU.S. President-Pharma BusinessMar 02Sale23.371,59537,27565,394Mar 04 04:09 PM
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'lMar 01Sale23.826,338150,971112,179Mar 02 09:29 PM
Spurr RobertU.S. President-Pharma BusinessFeb 15Sale25.023,25181,34060,299Feb 17 04:36 PM
Spurr RobertU.S. President-Pharma BusinessJan 18Sale26.633,25186,57463,550Jan 20 07:55 PM
Miller Steven DDirectorNov 30Buy24.1710,000241,69910,000Dec 02 07:15 PM
Miller Steven DDirectorNov 30Buy24.2450,0001,211,82560,780Dec 02 07:15 PM